Sunday, September 7, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today presented pivotal data

Tuesday, September 2, 2025

Nuvalent, Inc. (NASDAQ:NUVL) ranks among the best mid-cap stocks with huge upside potential. On August 19, Piper Sandler began coverage of Nuvalent, Inc. (NASDAQ:NUVL) with a price target of $112 and

Thursday, August 28, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Po

Wednesday, August 13, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal

Thursday, August 7, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and b

Monday, July 21, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the firs

Sunday, July 6, 2025

Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent announced positive pivotal data from its global ARROS-1 Phase 1/2 clinical tr

Sunday, June 29, 2025

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s s

Wednesday, June 25, 2025

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the compet

Wednesday, June 25, 2025

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nuvalent (NUVL) to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results f

Tuesday, June 24, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive pivo

Tuesday, June 24, 2025

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, a crowded indication with uncertain sales potential.

Tuesday, June 24, 2025

Presentation Operator MessageOperator Good morning, and welcome to Nuvalent conference call. [Operator Instructions] Please be advised that this call is being recorded at the company's request. I...

Tuesday, June 24, 2025

Nuvalent, Inc. announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer from the global...

Monday, June 23, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the comp

Wednesday, June 18, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointme

Thursday, May 8, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and b

Thursday, May 8, 2025

Nuvalent, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 84.58 million compared to USD 44.48 million a year...

Tuesday, April 29, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publicati

Thursday, April 24, 2025

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other takeover rumor stocks

Wednesday, April 23, 2025

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other Gu

Wednesday, April 23, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two "Trial in

Tuesday, April 8, 2025

Tuesday, April 1, 2025

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other debt free mi

Tuesday, April 1, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Po

Saturday, March 29, 2025

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other best mid cap biot

Tuesday, March 25, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced upcoming post

Thursday, March 20, 2025

Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.

Monday, March 3, 2025

CAMBRIDGE - Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James...

Thursday, February 27, 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and b

Tuesday, February 25, 2025

DelveInsight's, ALK-positive Non-Small Cell Lung Cancer Pipeline Insight report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer...

Tuesday, February 11, 2025

We recently compiled a list of the 10 Mid-Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other feminist

Wednesday, February 5, 2025

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Wednesday, January 22, 2025

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Read the full report on the stock here.

Monday, January 20, 2025

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against other Billi

Tuesday, January 14, 2025

CAMBRIDGE - Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline...

Friday, January 10, 2025

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results. Read my NUVL thesis.

Thursday, January 2, 2025

Headlines that Matter for Companies and Executives in Regulated Industries California Doctor to Pay $3 Million for Insider Trading On December 18, a California oncologist agreed to pay the US...

Monday, December 30, 2024

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Thursday, December 19, 2024

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Po

Monday, December 9, 2024

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointme

Monday, December 9, 2024

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE NUVALENT, INC. 2021 STOCK OPTION AND...

Saturday, December 7, 2024

Nuvalent, Inc. has promising drugs, zidesamtinib and NVL-655, targeting NSCLC with encouraging data. Read why NUVL stock is a Sell.

Tuesday, November 26, 2024

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Po

Wednesday, November 13, 2024

CAMBRIDGE - Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline...

Thursday, October 31, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 29, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, October 25, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 24, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 24, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 24, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 24, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 23, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 23, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 22, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 16, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 15, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 15, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 10, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, October 4, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, October 4, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, September 30, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, September 27, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, September 24, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, September 23, 2024

Nuvalent's promising lead candidates and strong investor interest has put the stock under the spotlight. Read more about the next steps for NUVL stock here.

Monday, September 23, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, September 19, 2024

Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.

Wednesday, September 18, 2024

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing o

Wednesday, September 18, 2024

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Wednesday, September 18, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, September 17, 2024

Learn about Nuvalent, Inc.'s promising new treatments for ALK and ROS-1 mutant NSCLC, with potential growth and shareholder benefits. Click for my NUVL update.

Tuesday, September 17, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, September 17, 2024

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read why I'm bearish on NUVL stock here.

Tuesday, September 17, 2024

Companies In The News Are: INTC, BA, NUVL, AA.

Tuesday, September 17, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, September 17, 2024

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing o